Krystal Biotech Q3 net income triples-March 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Krystal Biotech Q3 net income triples

Nov 3, 2025 4:29 AM

Overview

* Krystal Biotech Q3 2025 product revenue rises to $97.8 mln, up from $83.8 mln in 2024

* Net income for Q3 2025 increases to $79.4 mln from $27.2 mln in 2024

* Company launched VYJUVEK in Germany in Q3, France and Japan in Q4

Outlook

* Company expects cystic fibrosis interim data readout in Q4 2025

* Krystal Biotech ( KRYS ) anticipates pricing negotiations in Germany to continue until at least 2H 2026

* Company projects non-GAAP R&D and SG&A expenses between $145 mln and $155 mln for FY 2025

Result Drivers

* VYJUVEK LAUNCHES - Launched in Germany, contributing to revenue growth

* EXPANDED LABEL - FDA approval expanded VYJUVEK's eligible patient population in the U.S.

* HIGH GROSS MARGIN - Achieved a gross margin of 96% for the quarter

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $97.80

Product mln

Revenue

Q3 Net $79.36

Income mln

Q3 $56.42

Operatin mln

Expenses

Q3 $41.37

Operatin mln

g Income

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Previous page： --Vertex Pharmaceuticals Raises Full Year 2024 Product Revenue Guidance to $10.8-$10.9 Billion, vs Prior View of $10.65-$10.85 Billion Next page： Diamondback Energy misses estimates for third-quarter profit

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Vertex Pharmaceuticals Raises Full Year 2024 Product Revenue Guidance to $10.8-$10.9 Billion, vs Prior View of $10.65-$10.85 Billion

Nov 4, 2024

04:03 PM EST, 11/04/2024 (MT Newswires) -- Price: 468.00, Change: -3.12, Percent Change: -0.66 ...

Diamondback Energy misses estimates for third-quarter profit

Nov 4, 2024

Nov 4 (Reuters) - Diamondback Energy ( FANG ) missed estimates for third-quarter profit on Monday as the oil and gas firm was hurt by lower prices. The company reported an adjusted profit of $3.38 per share for the quarter ended Sept. 30, compared with analysts' average estimate of $3.98 per share, according to data compiled by LSEG. (Reporting by...

Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength

Nov 4, 2024

(Reuters) - Vertex Pharmaceuticals ( VRTX ) raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion. Analysts expect annual revenue of $10.75 billion, according to...

Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength

Nov 4, 2024

Nov 4 (Reuters) - Vertex Pharmaceuticals ( VRTX ) raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion. Analysts expect annual revenue of $10.75 billion,...